Recently, Lin Hua Medical announced that its controlling shareholder and actual controller Wu Linyuan was involved in arbitration, and the incident was caused by a joint acquisition a year ago. More than a year ago, Linhua Medical received a total of 15 million yuan from Beijing Zhaoshi Medical Devices Co., Ltd., which was originally owned by the respondent Zhao Xiaoyun (now the name has been changed to Beijing Yuetong Medical Devices Co., Ltd., hereinafter referred to as Beijing Yue Tong), did not expect that a year later, Wu Linyuan applied for arbitration Zhao Xiaoyun, asking him to return RMB 4 million. It is understood that Linhua Medical was founded in July 1989. It is mainly engaged in the research and development, production and sales of single-use injection puncture medical devices. The main products are intravenous indwelling needles, which belong to Class III medical devices under state supervision and management. Linhua Medical has developed optimistically in recent years and has good profitability. In 2015, its operating income was 377 million yuan, an increase of 19.48% over the same period of last year; net profit was 97.435 million yuan, an increase of 15.85% over the same period of the previous year. In 2016, the operating income was 500 million yuan, an increase of 32.71% over the same period of last year; the net profit was 132 million yuan, an increase of 35.71% over the same period of the previous year. In June 2016, Lin Hua Medical signed an agreement with Zhao Xiaoyun, the respondent of the arbitration, to agree that Zhao Xiaoyun holds a 100% stake in Beijing Zhaoshi Medical Devices Co., Ltd. (now the name has been changed to Beijing Yuetong Medical Devices Co., Ltd. ) Transferred to Linhua Medical for a consideration of 15 million yuan. Lin Hua Medical paid the full amount by July 22, 2016. The main business scope of Zhaoshi Medical includes the purchase and sale of medical equipment; the purchase and sale of mechanical and electrical equipment, electronic components and so on. At the same time, because of Zhao Xiaoyun's senior industry experience, Lin Hua Medical's controlling shareholder and actual controller Wu Linyuan signed an agreement with Zhao Xiaoyun as the general manager of the acquired subsidiary, responsible for the promotion of related work. If the work is completed, Wu Linyuan will pay Zhao Xiaoyun. 40 million yuan, and on August 9, 2016, prepaid 10% of the full amount, 4 million yuan. However, what I did not expect was that the "love period" of the two sides only lasted for 4 months. On December 28, 2016, Zhao Xiaoyun resigned as the general manager of Beijing Yuetong and left without permission because of his high age and physical discomfort. Beijing Yuetong decided to hire an executive director of Zhao Xiaoyun's position as a general manager after many times of advice and retention. Therefore, Wu Linyuan, the controlling shareholder and actual controller of Linhua Medical, believes that Zhao Xiaoyun’s behavior is in fundamental violation of the core agreement of the agreement, which has led to a serious obstruction of Beijing Yuetong’s production, R&D and PICC forensics, which cannot be promoted according to the established goals. The International Economic and Trade Arbitration Commission proposed a ruling on Zhao Xiaoyun. Zhao Xiaoyun was required to return the prepaid RMB 4 million; the payment terms stipulated in the agreement signed by the two parties could not be achieved, so Wu Linyuan did not need to pay Zhao Xiaoyun all the agreed money; the arbitration fee was borne by the respondent Zhao Xiaoyun. As for why the two sides ultimately failed to "live", why did Zhao Xiaoyun suddenly leave his job "self-willed", and whether there are any other insiders, no one knows. White Sesame Seeds,Roasted White Sesame Seed,Roasted White Sesame,Big Package White Sesame Seeds Chinese Seasoning (Shandong) Trading Co.,Ltd , https://www.zt-trading.com